Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
DSM Austria GmbH currently faces 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units, representing a perfectly decentralized prosecution profile. SWIFT, CANDICE LEE is the busiest examiner, currently overseeing 1 pending action.
The distribution of those matters across 4 distinct art units suggests a broad technical range within the company's Biotechnology & Pharmaceuticals portfolio. Because each of the examiners is handling only one matter, the applicant must manage four separate sets of examiner preferences and art unit cultures. This lack of overlap means that successful arguments in one case may not easily translate to the others.
Practitioners should prepare for a diverse array of prior art and legal objections, given that the matters are spread across those units. The reliance on 4 distinct examiners minimizes the risk of a single examiner's bias affecting the entire pending portfolio. SWIFT, CANDICE LEE manages 1 pending action, representing one of the four unique prosecution paths.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
| MOEHLMAN, ANDREW TERRY | 1 | 66.3% | +61.0% |
| MCLEOD, AFRICA MHAIRIE | 1 | 51.9% | +67.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683116 | BIOMARKER FOR TRICHOTHECENE TOXICITY | HANEY, AMANDA MARIE | — |
| 18001269 | TRUNCATED PROMOTOR FOR RECOMBINANT GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030883 | TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF | MOEHLMAN, ANDREW TERRY | 28d |
| 18685478 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | SWIFT, CANDICE LEE | — |
| 18683116 | BIOMARKER FOR TRICHOTHECENE TOXICITY | HANEY, AMANDA MARIE | — |
| 18001269 | TRUNCATED PROMOTOR FOR RECOMBINANT GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1682 | 1 |
| 1655 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685478 | MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A | SWIFT, CANDICE LEE | 1657 | §112 | Non-Final OA | — | Pending | Feb 21, 2024 |
| 18683116 | BIOMARKER FOR TRICHOTHECENE TOXICITY | HANEY, AMANDA MARIE | 1682 | §101§112 | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18030883 | TETRAMERIC ALPHA/BETA HYDROLASE VARIANTS WITH INCREASED TEMPERATURE STABILITY AND METHODS OF USING AND PRODUCING THEREOF | MOEHLMAN, ANDREW TERRY | 1655 | §112 | Final Rejection | 28d | Pending | Apr 07, 2023 |
| 18001269 | TRUNCATED PROMOTOR FOR RECOMBINANT GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | 1635 | §102§103§112 | Final Rejection | — | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial